Barclays PLC Buys 72,591 Shares of Liquidia Co. (NASDAQ:LQDA)

Barclays PLC raised its position in shares of Liquidia Co. (NASDAQ:LQDA - Free Report) by 265.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 99,984 shares of the company's stock after purchasing an additional 72,591 shares during the quarter. Barclays PLC owned 0.13% of Liquidia worth $999,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Whitefort Capital Management LP raised its position in Liquidia by 119.8% during the third quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company's stock valued at $17,020,000 after buying an additional 927,546 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of Liquidia by 144.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company's stock valued at $3,903,000 after purchasing an additional 230,820 shares during the period. Anson Funds Management LP acquired a new position in shares of Liquidia in the 3rd quarter valued at about $1,764,000. Sapient Capital LLC purchased a new stake in shares of Liquidia in the third quarter worth approximately $1,336,000. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Liquidia by 735.1% during the third quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company's stock worth $1,402,000 after purchasing an additional 123,402 shares during the period. Hedge funds and other institutional investors own 64.54% of the company's stock.

Insider Activity at Liquidia

In other Liquidia news, CEO Roger Jeffs sold 8,053 shares of the business's stock in a transaction on Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $89,468.83. Following the completion of the transaction, the chief executive officer now owns 812,193 shares of the company's stock, valued at $9,023,464.23. The trade was a 0.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Michael Kaseta sold 3,892 shares of the firm's stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $11.11, for a total value of $43,240.12. Following the completion of the sale, the chief financial officer now directly owns 311,076 shares in the company, valued at approximately $3,456,054.36. This represents a 1.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 22,007 shares of company stock valued at $245,780. Corporate insiders own 30.10% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on LQDA. Scotiabank began coverage on shares of Liquidia in a research report on Wednesday, October 16th. They issued a "sector outperform" rating and a $30.00 target price for the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $19.00 price target on shares of Liquidia in a research note on Thursday, November 14th. HC Wainwright reissued a "buy" rating and set a $29.00 price objective on shares of Liquidia in a research report on Thursday, November 14th. Lifesci Capital began coverage on Liquidia in a research note on Thursday, October 3rd. They issued an "outperform" rating and a $30.00 target price on the stock. Finally, Wells Fargo & Company initiated coverage on Liquidia in a research note on Friday, December 20th. They set an "overweight" rating and a $20.00 price target for the company. One analyst has rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $25.38.

Liquidia Stock Up 2.2 %

Shares of NASDAQ:LQDA traded up $0.25 on Tuesday, reaching $11.76. The company had a trading volume of 423,458 shares, compared to its average volume of 959,643. The stock has a market capitalization of $995.33 million, a P/E ratio of -7.21 and a beta of 0.22. The stock has a 50-day moving average price of $10.96 and a 200 day moving average price of $11.04. Liquidia Co. has a twelve month low of $8.26 and a twelve month high of $16.99.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).